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Abstract  
We report a case of a 62 year-old patient who developed Palmar-plantar erythrodysesthesia upon receiving four cycles of capacitabine-based 
chemotherapy. She was on post surgical adjuvant treatment for invasive well differentiated adenocarcinoma of the colon. The clinical and 
therapeutic aspects of this chemotherapeutic adverse effect are discussed. 
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Capecitabine is a chemotherapeutic agent that is widely used in the 
treatment of colorectal cancer. It a pro-drug of 5- fluorouracil (5-
FU), and gets activated in the tumour tissue through a three step 
reaction mediated by thymidine phosphorylase enzyme. This 
enzyme, together with that responsible for the breakdown of 5-FU, 
dihydropyrimidine dehydrogenase are thought to contribute to the 
development of Palmar-plantar erythrodysesthesia (PPE), a 
chemotherapy adverse effect that is frequently associated with 
capecitabine therapy [1, 2].  
  
  
Patient and observation 
 
A 62 year old female patient presented to oncology clinic with a 
diagnosis of colon cancer Duke C with liver metastasis, referred for 
adjuvant chemotherapy. She had initially been seen at her local 
hospital with a history of chronic constipation whereby 
hemicolectomy was done and a 19cm long colon was excised which 
included 3cm of tumour, 8cm from the distal resection margin 
extending to the serosal surfaces. Histology confirmed an invasive, 
well differentiated adenocarcinoma of the colon, Duke C with 
tumour extending into the serosa with lymphovascular and 
perineural involvement. Tumour deposits were also seen in the 
omentum. Resection margins and appendix were free of tumour, 
and no lymph nodes were identified. The Patient did well post 
operatively for two months before she presented to Moi Teaching 
and Referral Hospital with features of intestinal obstruction, which 
necessitated a repeat explorative laparatomy. Right hemicolectomy 
and omentectomy with lymph node dissection was done. Intra 
operatively, she was found to have liver metastatic lesions and 
omentum involvement. The patient was then referred to oncology 
clinic for palliative chemotherapy. At that point, the liver and renal 
function tests as well as complete blood count were within normal 
limits. The patient was then started on palliative adjuvant 
chemotherapy- XELOX regimen (oxaliplatin 120mgs and 
capecitabine 1500mgs twice daily), repeated three weekly. She 
received the first four cycles with no reported serious adverse 
events. She had only been on Vitamin supplements for the 
management of neuropathy after the third cycle. However, when 
she reported to the clinic for the 5th cycle, she presented with 
symptoms of erythema, swellings, pain and blisters on the palms of 
the hands and soles of the feet (Figure 1, Figure 2, Figure 3). A 
diagnosis of PPE was arrived at, and the capecitabine-based 
chemotherapy discontinued. The patient continued on the Vitamin 
supplements and the lesions had healed after two weeks (Figure 4, 
Figure 5), and Carcino- embryonic antigen (CEA) test was normal 
(6.3ng/dl). The patient was then started on oxaliplatin- irinotecan 
therapy (IROX regime) after a two month-break from the time the 





PPE, also referred to as hand-foot syndrome is a dermatologic 
adverse reaction that has been associated with some 
chemotherapeutic agents including docetaxel, cytarabine, 
doxorubicin, and fluorouracil and its pro-drug capecitabine [3]. It 
typically presents with dysthesias and tingling in hands and feet 
which may progress to blistering and ulceration [4]. The 
pathogenesis has not been well understood, but is thought to be 
due to damaged capillaries in the hands and feet leading to 
inflammatory reactions which have been postulated to be 
cyclooxygenase (COX)-2 mediated [5, 6]. Genetic variation in genes 
responsible for capecitabine metabolism have been reported to 
increase the risk of capecitabine-induced PPE [7, 8], and incidences 
of the adverse effect has been reported to be more common in 
black than white patients [9].Treatment remains largely 
symptomatic, with treatment interruption and dose reduction being 





Early detection of the adverse effect, treatment interruption, patient 
education, conservative management and dose reduction or 
discontinuation of capecitabine therapy ameliorates the adverse 
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Figure 1: blisters on the palms of the patient’s hand  
Figure 2: blisters on the right foot  
Figure 3: blisters on the left foot  
Figure 4: the patient’s palms showing the healed blisters  
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Figure 3: blisters on the left foot  
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Figure 5: the patient’s feet showing the healed blisters 
 
 
 
